Workflow
Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates
MDGLMadrigal Pharmaceuticals(MDGL) GlobeNewswire News Room·2024-08-07 11:00

Second-quarter 2024 net sales of 14.6millionRezdiffra™(resmetirom)coverageinplaceformorethan50percentofcommerciallives;lessthan5percentofRezdiffra−coveredlivesrequirebiopsyExpertguidelinesrecommendRezdiffraasfirst−linetherapyforpatientswithF2/F3NASH/MASHPlanstodirectlycommercializeresmetirominEuropefollowingEMAdecisionexpectedmid−year2025Reportscash,cashequivalents,restrictedcashandmarketablesecuritiesof14.6 million Rezdiffra™ (resmetirom) coverage in place for more than 50 percent of commercial lives; less than 5 percent of Rezdiffra-covered lives require biopsy Expert guidelines recommend Rezdiffra as first-line therapy for patients with F2/F3 NASH/MASH Plans to directly commercialize resmetirom in Europe following EMA decision expected mid-year 2025 Reports cash, cash equivalents, restricted cash and marketable securities of 1.1 billion at June 30, 2024 Company to host ...